Is Halozyme Therapeutics (HALO) a Buy Post Earnings?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best cheap biotech stocks to buy now. Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,222,507 | $216,874,721 | -3% | 0.13% |
| 2. | D E Shaw D. E. Shaw | 1,649,466 | $111,009,062 | -38% | 0.06% |
| 3. | Millennium Management Israel Englander | 1,463,948 | $98,523,700 | +20% | 0.04% |
| 4. | AQR Capital Management Cliff Asness | 1,158,359 | $77,957,548 | +20% | 0.04% |
| 5. | 40,851,000 | $54,243,628 | +42% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.95 | 2,671 | $189,494.10 | 767,780 | 2026-03-04 | Filing | |
| $69.94 | 7,329 | $512,619.58 | 770,451 | 2026-03-04 | Filing | |
| $69.33 | 6,519 | $451,981.83 | 767,780 | 2026-03-03 | Filing | |
| $68.85 | 13,481 | $928,166.85 | 774,299 | 2026-03-03 | Filing | |
| $70.46 | 578 | $40,726.46 | 767,780 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,153,857 | $885,254,609 | 0.01% | |
| 2. | 11,566,896 | $778,452,101 | 0.01% | |
| 3. | 5,121,672 | $344,688,526 | 0.01% | |
| 4. | 3,648,063 | $245,514,640 | 0.04% | |
| 5. | 2,733,832 | $183,986,863 | 0.01% |
News See All
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory
We came across a bullish thesis on Halozyme Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on HALO.
Halozyme (HALO) Loses 9% on Weak Earnings
In an updated report, Halozyme Therapeutics Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026Halozyme Therapeutics, Inc. misses on earnings expectations.
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating
On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C.
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance
Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the best mid-cap growth stocks to buy right now. On January 8, TD Cowen raised its price target on Halozyme to $90 from $79 and kept a Buy rating.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the 10 best new stocks to buy in Ray Dalio’s portfolio. On January 8, TD Cowen boosted Halozyme Therapeutics, Inc.
Hedge Fund Resource Center